Glimepiride Accord Healthcare

Glimepiride Accord Healthcare is a prescription oral medication that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic agent. It is supplied in tablet form (strength not specified) and is marketed in the European Union. The product works by stimulating insulin release from pancreatic beta cells, helping to lower blood glucose levels in adults with type 2 diabetes mellitus as part of a comprehensive treatment plan.

Glimepiride Accord Healthcare is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, usually in combination with diet and exercise.

- Used as monotherapy when diet, exercise, and weight control are insufficient. - Combined with other oral antidiabetic agents such as metformin to improve glycemic control. - May be added to basal insulin therapy in patients who need additional glucose lowering. - Considered for patients with stable renal function and no history of severe hypoglycemia. - Prescribed to help achieve individualized HbA1c targets as part of a broader diabetes management plan.

The safety profile of glimepiride includes a range of adverse effects that vary in frequency and severity.

Common: - Mild hypoglycemia, especially when meals are missed or delayed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity. - Transient fatigue or weakness.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as rash, pruritus, or angio‑edema. - Hematologic abnormalities including leukopenia or thrombocytopenia. - Liver enzyme elevations indicating possible hepatic injury. - Severe hypoglycemia requiring emergency medical attention.

Before initiating glimepiride therapy, clinicians should evaluate several patient‑specific factors to minimize risks.

- Assess renal and hepatic function; dose adjustment may be required in impairment. - Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning. - Caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Monitor for signs of hypoglycemia, especially when alcohol is consumed. - Consider drug interactions that may potentiate glucose‑lowering effects. - Educate patients on recognizing and managing low blood sugar episodes.

Glimepiride can interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Avoid: - Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can raise glimepiride plasma levels. - Discontinuation of corticosteroids or beta‑blockers without dose adjustment, leading to unexpected hypoglycemia.

Use with caution: - Anticoagulants (e.g., warfarin) – monitor INR as glimepiride may affect metabolism. - Thiazide diuretics – may increase risk of hyperglycemia; monitor blood glucose. - ACE inhibitors or ARBs – watch for renal function changes that could affect drug clearance. - Alcohol – can potentiate hypoglycemic episodes; advise limited intake.